tbuckley/cabot-search huggingface dataset:
Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m6A reader YTHDF3
Authors: Wen Ni, Su Yao, Yunxia Zhou, Yuanyuan Liu, Piao Huang, Aijun Zhou, Jingwen Liu, Liheng Che, Jianming Li
Journal: Molecular Cancer (2019)

Abstract Background YAP activation is crucial for cancer development including colorectal cancer (CRC). Nevertheless, it remains unclear whether N6-Methyladenosine (m 6 A) modified transcripts of long noncoding RNAs (lncRNAs) can regulate YAP activation in cancer progression. We investigated the functional link between lncRNAs and the m 6 A modification in YAP signaling and CRC progression. Methods YAP interacting lncRNAs were screened by RIP-sequencing, RNA FISH and immunofluorescence co-staining assays. Interaction between YAP and lncRNA GAS5 was studied by biochemical methods. MeRIP-sequencing combined with lncRNA-sequencing were used to identify the m 6 A modified targets of YTHDF3 in CRC. Gain-of-function and Loss-of-function analysis were performed to measure the function of GAS5-YAP-YTHDF3 axis in CRC progression in vitro and in vivo. Results GAS5 directly interacts with WW domain of YAP to facilitate translocation of endogenous YAP from the nucleus to the cytoplasm and promotes phosphorylation and subsequently ubiquitin-mediated degradation of YAP to inhibit CRC progression in vitro and in vivo. Notably, we demonstrate the m 6 A reader YTHDF3 not only a novel target of YAP but also a key player in YAP signaling by facilitating m 6 A-modified lncRNA GAS5 degradation, which profile a new insight into CRC progression. Clinically, lncRNA GAS5 expressions is negatively correlated with YAP and YTHDF3 protein levels in tumors from CRC patients. Conclusions Our study uncovers a negative functional loop of lncRNA GAS5-YAP-YTHDF3 axis, and identifies a new mechanism for m 6 A-induced decay of GAS5 on YAP signaling in progression of CRC which may offer a promising approach for CRC treatment.
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
Authors: Carryn M. Anderson, Christopher M. Lee, Deborah P. Saunders, Amarinthia Curtis, Neal Dunlap, Chaitali Nangia, Arielle S. Lee, Sharon M. Gordon, Philip Kovoor, Roberto Arevalo-Araujo, Voichita Bar-Ad, Abhinand Peddada, Kyle Colvett, Douglas Miller, Anshu K. Jain, James Wheeler, Dukagjin Blakaj, Marcelo Bonomi, Sanjiv S. Agarwala, Madhur Garg, Francis Worden, Jon Holmlund, Jeffrey M. Brill, Matt Downs, Stephen T. Sonis, Sanford Katz, John M. Buatti
Journal: Journal of Clinical Oncology (2019)

PURPOSE Oral mucositis (OM) remains a common, debilitating toxicity of radiation therapy (RT) for head and neck cancer. The goal of this phase IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy and safety of GC4419, a superoxide dismutase mimetic, with placebo to reduce the duration, incidence, and severity of severe OM (SOM). PATIENTS AND METHODS A total of 223 patients (from 44 institutions) with locally advanced oral cavity or oropharynx cancer planned to be treated with definitive or postoperative intensity-modulated RT (IMRT; 60 to 72 Gy [≥ 50 Gy to two or more oral sites]) plus cisplatin (weekly or every 3 weeks) were randomly assigned to receive 30 mg (n = 73) or 90 mg (n = 76) of GC4419 or to receive placebo (n = 74) by 60-minute intravenous administration before each IMRT fraction. WHO grade of OM was assessed biweekly during IMRT and then weekly for up to 8 weeks after IMRT. The primary endpoint was duration of SOM tested for each active dose level versus placebo (intent-to-treat population, two-sided α of .05). The National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, was used for adverse event grading. RESULTS Baseline patient and tumor characteristics as well as treatment delivery were balanced. With 90 mg GC4419 versus placebo, SOM duration was significantly reduced ( P = .024; median, 1.5 v 19 days). SOM incidence (43% v 65%; P = .009) and severity (grade 4 incidence, 16% v 30%; P = .045) also were improved. Intermediate improvements were seen with the 30-mg dose. Safety was comparable across arms, with no significant GC4419-specific toxicity nor increase of known toxicities of IMRT plus cisplatin. The 2-year follow-up for tumor outcomes is ongoing. CONCLUSION GC4419 at a dose of 90 mg produced a significant, clinically meaningful reduction of SOM duration, incidence, and severity with acceptable safety. A phase III trial (ROMAN; ClinicalTrials.gov identifier: NCT03689712 ) has begun.
Abstract 280: The Effect of YAP/TAZ on Glycolysis and Mitochondrial Oxidative Phosphorylation in Cardiomyocytes
Authors: Toshihide Kashihara, Junichi Sadoshima
Journal: Circulation Research (2019)

The heart requires a high rate of adenosine triphosphate (ATP) production to maintain healthy cardiac function and viability. Anaerobic glycolysis and mitochondrial oxidative phosphorylation (OXPHOS) are the main metabolic pathways by which ATP is generated in mammalian cells, including cardiomyocytes. Yes-associated protein 1 (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), which are major downstream effectors of the Hippo signaling pathway, play an important role in the regulation of heart size and cellular homeostasis of cardiomyocytes. However, interplay between YAP/TAZ and cardiac energy metabolism has been poorly understood. Here we examined the effect of YAP/TAZ on glycolysis and OXPHOS in isolated neonatal rat ventricular cardiomyocytes (NRVMs). Extracellular acidification rate (ECAR; an index of glycolysis) and oxygen consumption rate (OCR; an index of OXPHOS) of NRVMs transduced with adenoviruses harboring YAP, TAZ, or LacZ (control) for 6 days were assessed by Seahorse XFe96 analyzer. Both YAP and TAZ significantly increased not only the ECAR of basal glycolysis (1.5-fold and 1.3-fold, respectively, p&lt;0.05), glycolytic maximal capacity (1.4-fold and 1.3-fold, respectively, p&lt;0.05), and glycolytic reserve capacity (1.3-fold and 1.2-fold, respectively, P&lt;0.05) (n=12-15) but also basal OCR (1.3-fold and 1.3-fold, respectively, p&lt;0.05) (n=6-10) compared to control LacZ. Quantitative PCR analysis showed that mRNA levels of Pfkm, a key glycolytic enzyme, and subunits of protein complexes I though V in the electron transport chain are significantly increased (1.3-1.9-fold, n=5-6, p&lt;0.05) by both YAP and TAZ compared with control. These results suggest that YAP/TAZ increase ATP production by accelerating glycolysis and OXPHOS in cardiomyocytes.
Utilizing visualization to qualitatively evaluate electronic health record-derived database limitations.
Authors: Aidan Gilbert, Pravinkumar Kandhare, Arie Nakhmani, Stephen C. Meersman, Elizabeth Garrett-Mayer, Melinda Kaltenbaugh, Mark E. Burkard, Courtney Williams, Andres Azuero, Smita Bhatia, Kelly Kenzik, Gabrielle Betty Rocque
Journal: Journal of Clinical Oncology (2019)

317 Background: Electronic health record (EHR) databases are a promising platform for clinical research using real-world data. However, information on potential limitations of these data sources is lacking. We sought to understand how data visualization might be used to identify data inconsistencies and the applicability of previously validated claims-based algorithms used to identify patients with metastatic breast cancer (MBC). Methods: This retrospective study utilized ASCO’s CancerLinQ Discovery database derived from EHR data. Subjects included women ≥18 years treated for MBC diagnosed ≥1980. Subjects with MBC were identified using two billing codes for metastasis on separate dates following primary breast cancer diagnosis. Treatment course sequences were visualized. Patients were represented by a horizontal bar on the Y-axis. Treatments were displayed using colored bars (blue: chemotherapy, red: endocrine therapy, green: HER2 targeted, orange: novel therapy) with time of treatment on the X-axis. Visualizations were qualitatively evaluated, and treatment patterns inconsistent with clinical practice were identified. Results: We identified 4,760 women treated for MBC using billing codes for primary breast cancer diagnosis and distant metastasis. Most patients (96%) had a primary breast cancer diagnosed in 2000 later. Treatment patterns inconsistent with clinical practice identified using the visualization technique included: 1% of patients received adjuvant chemotherapy continuously for ≥1.5 years, suggesting missed coding for metastatic disease; 5% of patients did not receive any treatment in the year following metastasis, suggesting the billing code may have been used in workup and not for confirmed metastatic disease. Among patients with MBC, 50% identified as HR+ across all records had not received hormone therapy, while 39% identified as HR- across all records received hormone therapy. Conclusions: Because previously validated algorithms may not translate well to EHR databases, quality auditing should always be performed. The proposed data visualization can be used for improving algorithms, qualitatively identifying errors, and avoiding biased or inaccurate results.
Composition of Classical Hodgkin Lymphoma Microenvironment Is Associated with Clinical Outcome
Authors: Olga Novosad, Tetiana Skrypets, Nataliia Svergun, Oksana Skachkova, Oleksandr Gorbach, Nataliia Khranovska, Mykhailo Krotevych, Larisa Skoroda, Maryna Koshubarova, Dmitry Novikov, Iryna Kriachok
Journal: Blood (2018)
Intestinal Immune Conditioning with Helminths Employs Host T Helper 2 (Th2) Pathway to Induce Mixed Chimerism and Regulate Graft-Versus-Host Disease
Authors: Jamie Truscott, Xiaoqun Guan, Wieren Liu, Sonay Beyatli, Ahmed Metwali, David E Elliot, Bruce R. Blazar, M. Nedim Ince
Journal: Blood (2018)
A Clinical Study of Bone Marrow Stromal Cell Therapy in Patients with Refractory Cgvhd by Down-Regulating the Jagged2 Gene
Authors: Jianyu Weng, Xin Huang, Suxia Geng, Chengwei Luo, Suijing Wu, Wei Ling, Rong Guo, Zesheng Lu, Chengxin Deng, Pengxiang Andy, Xin Du
Journal: Blood (2012)
A survey-based study of diagnostic and treatment concordance in standardized cases of cellulitis and pseudocellulitis via teledermatology
Authors: Abraham M. Korman, Daniela Kroshinsky, Adam B. Raff, Arash Mostaghimi, Robert G. Micheletti, Misha Rosenbach, Benjamin H. Kaffenberger, Adela R. Cardones, Arturo R. Dominguez, Alisa N. Femia, Jesse J. Keller, Daniel Li, Sahand Rahnama-Moghadam, Sabrina Newman, Megan H. Noe, Tejesh Patel, Kanade Shinkai, Michi M. Shinohara, Lucia Seminario
Journal: Journal of the American Academy of Dermatology (2019)
Protective Effects of Higher Cytomegalovirus Virus Load in Patients with Acute Myeloid Leukemia after Umbilical Cord Blood Transplantation
Authors: Manyu Dong, Zimin Sun, Xiaoyu Zhu, Baolin Tang, Kaidi Song, Xiang Wan, Yao Wen, Xuhan Zhang, Lei Zhang, Huilan Liu, Lijun Xia
Journal: Blood (2018)
Abstract 621: Cardiac Myosin Binding Protein-C Phosphorylation in Ser-273 and Ser-282 is Critical to Maintain Cardiac Function During Aging
Authors: Paola C Rosas, Chad M Warren, Ashley Batra, Heidi Creed, R J Solaro, Carl W Tong
Journal: Circulation Research (2019)

Background/hypothesis: Heart failure (HF) afflicts 6.2M Americans as of 2019 and its prevalence is expected to increase due to a growing aging population. HF progression involves depression in contractility and relaxation, which are strongly controlled by phosphorylation of cardiac myosin binding protein-C (cMyBP-C). We hypothesize that phosphorylated cMyBP-C supports normal heart function during aging. Methods: We aged mouse models of cMyBP-C de-phosphorylation mimetic (t3SA: S273A/S282A/S302A mutations), phosphorylation mimetic (t3SD: S273D/S282D/S302D mutations) and WT equivalent expressed onto cMyBP-C(-/-) background (tWT). Results: Western blotting (N=16, 2-24 months) showed that cMyBP-C phosphorylation decreases with aging at S273 and S282, showing strong Pearson correlations with age (see figure; S273P r= -0.931, p&lt;0.0001; S282P r=-0.868, p&lt;0.00001). Simultaneous force and [Ca 2+ ] i measurements on intact papillary muscles showed that phosphorylation-mimetic t3SD has greatest dFR=(-dF/dt)min/(+dF/dt)max, signifying better lusitropy with similar calcium decay rate constant (k Ca ) as others. Echocardiography at 3, 12, 15, 18 months showed that t3SD has preserved ejection fraction, faster peak myocardial relaxation velocity e’ and preserved posterior ventricular wall thickness with aging. Moreover, t3SD demonstrated superior 600-days survival than others (t3SD 87.5% n=96; tWT 69.3% n=122; t3SA 53.2% n=97; overall LogRank p=0.0002244). Conclusions: De-phosphorylation of cMyBP-C at S273 and S282 contributes to worsening of cardiac function with aging. Conversely, phosphorylated cMyBP-C mitigates aging-related cardiac dysfunction.
Silencing HDAC3 Enhances Apoptosis of Acute B Lymphoblastic Leukemia Cells smurf2 Inducing By Inhibiting JAK/STAT3 Signal Pathway
Authors: Yongling Guo, Dan Ma, Zhengchang He, Jie Xiong, Xingyi Kuang, Weili Wang, Kunling Yu, Zhaoyuan Zhang, Jishi Wang
Journal: Blood (2018)
LIN28A-Mediated Expression Of Fetal Hemoglobin Ameliorates Erythrocyte Sickling
Authors: Jaira F. de Vasconcellos, Ross M. Fasano, Y. Terry Lee, Megha Kaushal, Colleen Byrnes, Emily Riehm Meier, Molly Anderson, Ki Soon Kim, Antoinette Rabel, Raul C. Braylan, David Stroncek, Jeffery L. Miller
Journal: Blood (2013)
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial
Authors: Christian Carrie, Nicolas Magné, Patricia Burban-Provost, Paul Sargos, Igor Latorzeff, Jean-Léon Lagrange, Stéphane Supiot, Yazid Belkacemi, Didier Peiffert, Nedla Allouache, Bernard M Dubray, Stéphanie Servagi-Vernat, Jean-Philippe Suchaud, Gilles Crehange, Stéphane Guerif, Meryem Brihoum, Nicolas Barbier, Pierre Graff-Cailleaud, Alain Ruffion, Sophie Dussart, Céline Ferlay, Sylvie Chabaud
Journal: The Lancet Oncology (2019)
Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement
Authors: Brian L. Graham, Irene Steenbruggen, Martin R. Miller, Igor Z. Barjaktarevic, Brendan G. Cooper, Graham L. Hall, Teal S. Hallstrand, David A. Kaminsky, Kevin McCarthy, Meredith C. McCormack, Cristine E. Oropez, Margaret Rosenfeld, Sanja Stanojevic, Maureen P. Swanney, Bruce R. Thompson
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsThe Patient ExperienceIndicationsRelative Contraindication...Laboratory DetailsHygiene and Infection Con...EquipmentDevice Quality AssuranceOperator DetailsPatient DetailsFEV1 and FVC ManeuverBronchodilator Responsive...Reported ValuesGrading the Quality of th...VC and Inspiratory Capaci...Further StudiesReferencesCITING ARTICLES
Early Recovery Of Absolute Lymphocyte Counts ≥ 0.2x109/L At Day 21 Can Predict Reduced Risk Of Relapse In Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation
Authors: Feras Abdulaziz Alfraih, Dennis Dong Hwan Kim, John Kuruvilla, Hans A. Messner, Jeffrey H. Lipton, Vikas Gupta
Journal: Blood (2013)
Arginine Depletion in Combination with Canavanine Supplementation Induces Massive Cell Death in Myeloma Cells By Interfering with Their Protein Metabolism and Bypassing Potential Rescue Mechanisms
Authors: Johannes Windschmitt, Björn Jacobi, Yagmur Bülbül, Lilli Sester, Janine Tappe, Christof Hiebel, Christian Behl, Matthias Theobald, Markus Munder
Journal: Blood (2018)
Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice
Authors: Emilia Scalzulli, Matteo Molica, Alunni Fegatelli Danilo, Lorenzo Rizzo, Roberto Latagliata, Robin Foà, Massimo Breccia
Journal: Blood (2018)
Selective Targeting of B Cells with Mesenchymal Stromal Cells Treatment Is An Efficacious Strategy for Cutaneous Cgvhd,
Authors: Peilong Lai, Jianyu Weng, Chenwei Luo, Rong Guo, Zesheng Lu, Suxia Geng, Xin Du, Suijing Wu
Journal: Blood (2011)
Abstract 722: Unveiling Ccbe1 Role as a Modulator of Cardiomyocyte Differentiation
Authors: Marta M Silva, Pedro Vicente, Daniel Simão, Ana P Terrasso, José M Inácio, José A Belo, Patrícia Gomes-Alves, Margarida Serra, Paula M Alves
Journal: Circulation Research (2019)

Chronic heart failure is a major unmet clinical need arising from the loss of viable and functional cardiac muscle, representing a major cause of mortality worldwide. There is a need to identify key molecules and signaling pathways acting on the coronary vasculature system towards regenerative therapies. Human induced pluripotent stem cells (hiPSC) are an attractive cell source to understand the regulatory networks involved in cardiac commitment and cardiomyocyte (CM) differentiation. Particularly, CCBE1 (collagen and calcium-EGF biding domain 1) has been studied as a secreted protein critical for lymphatic/cardiac vascular development and recent reports have proposed that CCBE1 may potentially be used to restore cardiac tissue upon heart injury, through CCBE1-mediated cardiac commitment and/or augmentation of lymphangiogenesis. Therefore, the goal of our work is to understand the molecular pathways underlying CCBE1-based cardiac commitment in loss-of-function studies. By exploring gene editing and “omics” tools we aim to unveil the molecular basis of CCBE1-induced cardiogenesis and provide novel insights towards the development of CCBE1-mediated therapeutic strategies for cardiac regenerative medicine. To selectively knock-down (KD) CCBE1 expression along hiPSC cardiac differentiation, we used modified hiPSC line with CRISPR interference technology (CRISPRi-hiPSC). The CCBE1 KD led to a reduction on the expression of cardiac troponin marker TNNT2 and on the ratios of MYH7:MYH6 and TNNI3:TNNI1. The CCBE1 KD-derived CMs also presented an immature-related ultrastructure, suggesting that CCBE1 may modulate the CM phenotype. On the other hand, the EC differentiation was not impaired by CCBE1 KD. A comprehensive and integrated characterization of the transcriptome and proteome along the differentiation in the presence or absence of CCBE1 is being pursued to identify the key players at cardiac mesoderm and cardiac progenitors stages and their interactions with CCBE1. This work opens new avenues for the identification of CCBE1-modulated proteins/pathways in cardiac commitment, which may contribute for novel cell-based or cell-free approaches towards more efficacious cardiac regenerative therapies.
Diversity and Inclusion—One Size Does Not Fit All
Authors: Keon Young Park, Scott R. Chaiet, Caprice C. Greenberg
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Persistence of Somatic Mutation Spectrum and Clonal Architecture in Chronic Myelomonocytic Leukemia Treated with Hypomethylating Agents
Authors: Hein Than, Yi Qiao, Xiaomeng Huang, Dongqing Yan, Jamshid Sorouri Khorashad, Anthony D. Pomicter, Anca Franzini, Tibor Kovacsovics, Thomas O'Hare, Gabor T. Marth, Michael W. Deininger
Journal: Blood (2017)
Return-to-sport testing following ACL reconstruction revisited
Authors: Kate E Webster, Timothy E Hewett
Journal: British Journal of Sports Medicine (2019)

In our recent systematic review and meta-analysis,1 one of the questions posed was: Is passing return-to-sport (RTS) test batteries associated with reduced rates of subsequent knee injury?1 The aim of this editorial is to comment on debate2 about the methodology used to avoid further confusion with regard to relevant data and conclusions that can be drawn from the existent literature. Concerns raised centred on two aspects: appraisal of risk-of-bias and pooling data from heterogenous samples, both of which impact on study selection. These are discussed separately.

For risk-of-bias assessment, two tools provided by the National Institutes of Health were used. While one could argue the semantics of using the terminology ‘risk-of-bias’ versus ‘quality assessment’—we acknowledge that we used both—the content of the assessment was clearly in line with what Capin et al 2 suggest should be included in such an assessment. Full details of the assessment can be accessed in the online supplementary appendix to our article. It is possible that this appendix has been overlooked.

It must be understood that the two studies excluded by Capin et …
Analysis of BRCA1 and BRCA2 Mutations and Gene Expression in Hematological Malignancies - Implications for Differential Involvement in Pathogenesis of Lymphoid Neoplasms
Authors: Anna Stengel, Wencke Walter, Stephan Hutter, Wolfgang Kern, Manja Meggendorfer, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2018)
Abstract 540: Sigma 1 Receptor-dependent Regulation of Mitochondrial Respiration and Function in Cardiomyocytes
Authors: Richa Aishwarya, Md. Shenuarin Bhuiyan
Journal: Circulation Research (2019)

Background: Sigma 1 receptor (Sigmar1) is an abundantly expressed molecular chaperone protein in cardiomyocytes. Sigmar1 ligands have been shown to have protective function in animal models of cardiac hypertrophy, heart failure, and many other cardiovascular disorders. Despite extensive studies, the physiological and molecular functions of Sigmar1 in cardiomyocytes remains elusive. Objective: We investigated the molecular function of Sigmar1 in regulating mitochondrial respiration and function in cardiomyocytes. Methods and Results: To define the molecular function of Sigmar1 in regulating mitochondrial respiration and function in cardiomyocytes, we used small interfering RNA-mediated Sigmar1 knockdown and adenovirus-mediated overexpression in cultured neonatal rat ventricular cardiomyocytes. Sigmar1 knockdown in neonatal cardiomyocytes showed significantly decreased mitochondrial respiration measured by Seahorse Analyzer. Mitochondria stained with mitoTracker green showed a significantly increased number of hyperfused mitochondria in Sigmar1 knockdown cardiomyocytes. Similarly, mitochondria isolated from Sigmar1 global knockout mouse hearts also showed decreased mitochondrial respiration and the accumulation of larger size mitochondria measured by flowcytometry. Sigmar1 overexpression in cardiomyocytes significantly increased mitochondrial respiration and also showed increased mitochondrial fragmentation. Conclusions: Our findings suggested that Sigmar1 plays an essential role in maintaining normal mitochondrial morphology, respiration, and function in cardiomyocytes.